Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer to help develop and market Eisai's Alzheimer's drug

Executive Summary

Eisai Co. and Pfizer will collaborate on development and marketing of Eisai's E2020 once-daily Alzheimer's drug. A joint committee will also plan development of Pfizer's CP-118,954 (Phase II) and other products for treating dementia.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Co-Promotion
    • Product or Technology Swap
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register